Author name: abldadmin

https://www.einpresswire.com/article/916012021/abl-diagnostics-broadens-ultragene-syndromic-qpcr-portfolio

https://www.einpresswire.com/article/915738686/ultragene-ebola-multiplex-qpcr-for-outbreak-preparedness

https://www.einpresswire.com/article/914346495/abl-diagnostics-advances-ngs-for-cmv-resistance-monitoring-at-seimc-2026

https://www.einpresswire.com/article/914324401/abl-diagnostics-et-le-chru-nancy-premier-bilan-positif-pour-le-projet-predavir-apr-s-6-mois

https://www.einpresswire.com/article/913871100/abl-diagnostics-drives-emea-expansion-with-vela-diagnostics-partnership

https://www.einpresswire.com/article/913010661/abl-diagnostics-unveils-next-generation-hiv-genotyping-innovation-with-the-industry-s-broadest-portfolio

https://www.abldiagnostics.com/wp-content/uploads/2026/05/P190.pdf

Official Presentation of the DeepChek® HPV Messenger RNA Genotyping Assay Webinar from June 26, 11h00 CET / Paris time https://ablsa-my.sharepoint.com/:f:/p/matthieu_barralon/EoLXon5w0g9AhQlr5kZTO_gBQ9TVE9AcQJuJu_Cw_9Y1Jw?e=OU2KLh

ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, is pleased to announce an exclusive distribution agreement with Riken Genesis Co., Ltd. (https://www.rikengenesis.jp/en.html). Under this partnership, Riken Genesis will promote and commercialize ABLD’s DeepChek® and UltraGene molecular assays across laboratories in Japan, further strengthening its diagnostics portfolio. Through this collaboration, Riken Genesis

REAL LIFE EXPERIENCE: The relevance of ultradeep sequencing for low HIV‐1 viral loads and proviruses in the clinical setting Webinar from Tuesday November 19, 2024 – 4pm CEST https://ablsa-my.sharepoint.com/:f:/p/matthieu_barralon/EoLXon5w0g9AhQlr5kZTO_gBQ9TVE9AcQJuJu_Cw_9Y1Jw?e=OU2KLh